AMP-activated protein kinase as a drug target in chronic kidney disease
المؤلف | Allouch S. |
المؤلف | Munusamy S. |
تاريخ الإتاحة | 2020-03-29T12:12:12Z |
تاريخ النشر | 2018 |
اسم المنشور | Current Drug Targets |
المصدر | Scopus |
الرقم المعياري الدولي للكتاب | 13894501 |
الملخص | Background: Chronic kidney disease (CKD) is a condition increasingly affecting millions of individuals worldwide and is ranked as the ninth leading cause of death in the United States. AMP-activated protein kinase (AMPK) is an energy sensor that plays a pivotal role in cellular homoeostasis. Deficiency in AMPK activity and autophagic signaling, and sustained activation of mammalian target of rapamycin (mTOR) signaling and endoplasmic reticulum (ER) stress have been shown to promote epithelial-to-mesenchymal transition (EMT) and renal cell apoptosis and contribute to CKD. Emerging evidences demonstrate that AMPK acts as a modulator of the aforementioned pathways that underpin the pathophysiology of CKD. Furthermore, pharmacological activators of AMPK such as metformin have been shown to exert renoprotective effects in experimental studies and improve clinical outcomes in patients with CKD. Objective: The current review focuses on the nephroprotective effects of AMPK and its utility as a therapeutic target for the prevention and treatment of CKD. |
اللغة | en |
الناشر | Bentham Science Publishers B.V. |
الموضوع | AMP-activated protein kinase Apoptosis Autophagy Chronic kidney disease Endoplasmic reticulum stress Epithelial-mesenchymal transition Mammalian target of rapamycin Metformin |
النوع | Article Review |
الصفحات | 709-720 |
رقم العدد | 6 |
رقم المجلد | 19 |
الملفات في هذه التسجيلة
الملفات | الحجم | الصيغة | العرض |
---|---|---|---|
لا توجد ملفات لها صلة بهذه التسجيلة. |
هذه التسجيلة تظهر في المجموعات التالية
-
أبحاث الصيدلة [1234 items ]